Spectrum Pharmaceuticals Has Ample Supplies of FUSILEV to Meet the Growing Demand of Colorectal Cancer Patients in the U.S.

Spectrum Pharmaceuticals SPPI announced today that during the second quarter the Company has worked closely with the U.S. Food & Drug Administration on securing multiple sources of U.S. manufacturing for the Company's anti-cancer drug, FUSILEV, approved on April 29, 2011 for use in the palliative treatment of patients with advanced metastatic colorectal cancer. Spectrum believes it has secured ample FUSILEV manufacturing capacity to meet the current and anticipated demand in patients undergoing treatment for colorectal cancer.